|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study reveals that GP73 plays functional roles in the trafficking and equilibrium of epithelial-mesenchymal transition (EMT)-related secretory proteins and that GP73 serves as a new potential target for combating the metastasis of HCC.
|
30677226 |
2019 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, serum GP73 is not a suitable diagnostic marker for HCC.
|
28157705 |
2017 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The ectopic overexpression of GP73 increased HCC cell invasion, EMT and metastasis both in vitro and in vivo.
|
29365054 |
2018 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
LHGDN |
We conclude that the endosomal trafficking of GP73 allows for PC-mediated cleavage, resulting in GP73 secretion, and provides a molecular mechanism for its presence as a serum biomarker for HCC.
|
17662025 |
2007 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
GP73-SphK1sR-Ad5 was constructed by integrating Golgi protein 73 (GP73) promoter and sphingosine kinase 1 (SphK1)-short hairpin RNA (shRNA) into adenovirus serotype 5 (Ad5), and transfecting into HCC Huh7 cells and normal human liver HL-7702 cells.
|
31749347 |
2020 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We used MTS assays, anchorage-independent cell colony formation assays and a xenograft tumor model to show that GP73-specific siRNAs inhibit HCC proliferation in HepG2, SMMC-7721, and Huh7 cell lines and in vivo.
|
26870893 |
2016 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The aim of this study was to evaluate the predictive value of serum GP73 level for posthepatectomy short-term outcomes in hepatocellular carcinoma (HCC) patients.
|
31046807 |
2019 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings reveal the functional role of GOLM1, a Golgi-related protein, in EGFR/RTK recycling and metastatic progression of HCC.
|
27569582 |
2016 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Expression of GP73 was upregulated in the more metastatic HCC cell lines.
|
28075476 |
2017 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
GP73 is a transmembrane glycoprotein that increases in viral and non-viral liver diseases, especially in hepatocellular carcinoma.
|
31495236 |
2019 |
|
Liver carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Serum levels of α-fetoprotein (AFP), AFP-L3, des-γ-carboxy prothrombin (DCP), and Golgi protein 73 (GP73) were analyzed in 114 advanced HCC patients, 81 early stage HCC patients, and 152 LC patients.
|
29113322 |
2017 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In addition, upregulated GP73 in HCC tissues was inversely correlated with the miR-493-5p expression levels in the HCC tissues.
|
28419971 |
2017 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study increases our understanding of the functional relevance of GP73 glycosylation and suggests that Asn144-deleted GP73 can influence the progression and metastasis of hepatocellular carcinoma.
|
26993603 |
2016 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, our results highlighted that miR-382, a novel prognostic factor, target GOLM1 to inhibit metastasis of hepatocellular carcinoma.
|
29416925 |
2018 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression of miR-27b was significantly lower in HCC tissues with high expression of GP73, when compared with adjacent nontumor tissues.
|
30418194 |
2019 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Golgi protein 73 (GP73) is a potential hepatocellular carcinoma serum marker with better sensitivity and specificity.
|
30327105 |
2018 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Interleukin-6 and oncostatin M are elevated in liver disease in conjunction with candidate hepatocellular carcinoma biomarker GP73.
|
23144154 |
2012 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Golgi protein 73 (GP73), which is up-regulated in hepatocellular carcinoma (HCC), has recently been identified as a novel serum marker for HCC diagnosis.
|
24351813 |
2013 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Levels of GP73 and MMP-13 are increased and positively correlated in human HCC tissues.
|
26378022 |
2015 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
GOLPH2 is prominently overexpressed in hepatocellular carcinoma, melanoma, glioblastoma, prostate, lung, and colorectal cancer.
|
31541350 |
2019 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
For patients with liver cirrhosis (n = 19), the AFP was 2.60 (1.70, 4.20) μg/l and GP73 was 136.10 (92.10, 261.70) μg/l, and for HCC patients (n = 36), the AFP was 13.65 (3.35, 158.88) μg/l and GP73 was 186.25 (96.73, 262.03) μg/l.
|
29630871 |
2018 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
LHGDN |
Using mass spectrometry, we have established that at least two of three potential sites of N-linked glycosylation are occupied on most molecules of GP73 secreted from cultured hepatoma cells.
|
18004786 |
2008 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Golgi protein 73 (GP73) is a novel and potential marker for diagnosing hepatocellular carcinoma (HCC) that has been found to be abnormally elevated in liver disease.
|
28054632 |
2017 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Significantly higher levels of GP-73 and PIVKA-II were detected in the HCC group than in all other groups, while MIF showed a highly significant increase in HCC from all groups except the cancer control group.
|
28276727 |
2017 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings suggest that GP73 is a potential target for combating metastatic HCC.
|
31591387 |
2019 |